Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 14/20 | 0.71 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.55 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.54 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4736241 | 1.00 | ACHE (0.71) | ACHEEPHX1EPHX2PAOX | |
| SCHEMBL7677452 | 1.00 | ACHE (0.71) | ACHEEPHX1EPHX2PAOX | |
| SCHEMBL6950987 | 1.00 | ACHE (0.71) | ACHEEPHX1EPHX2PAOX | |
| SCHEMBL29991047 | 1.00 | ACHE (0.71) | ACHEEPHX1EPHX2PAOX | |
| SCHEMBL6269354 | 0.98 | ACHE (0.68) | ACHEEPHX1EPHX2 | |
| SCHEMBL856878 | 0.93 | ACHE (0.70) | ACHEEPHX2 | |
| SCHEMBL8086223 | 0.92 | ACHE (0.60) | ACHEEPHX1EPHX2 | |
| SCHEMBL13114886 | 0.91 | ACHE (0.62) | ACHEEPHX1EPHX2PAOX | |
| SCHEMBL473096 | 0.91 | ACHE (0.85) | ACHEEPHX1EPHX2 | |
| SCHEMBL10447924 | 0.91 | ACHE (0.85) | ACHEEPHX1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024089248-A1 | RECOMBINANT ACTIVATION-ASSOCIATED SECRETED PROTEIN | UNIVERSITEIT GENT (BE) | 2024-05-02 | — | — | WO | disclosed |
| WO-2023220640-A1 | CDK PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023180743-A1 | ZIP12 ANTIBODY | Apollo AP13 Limited (GB) | 2023-09-28 | — | — | WO | disclosed |
| EP-4010368-A1 | ANTI-NAMPT ANTIBODIES AND USES THEREOF | Aqualung Therapeutics Corp. (US) | 2022-06-15 | — | — | EP | disclosed |
| EP-3986887-A1 | TARGETED PROTEIN DEGRADATION OF PARP14 FOR USE IN THERAPY | Ribon Therapeutics Inc. (US) | 2022-04-27 | — | — | EP | disclosed |
| US-20220074941-A1 | HSP90 COMBINATION THERAPY | SLOAN KETTERING INST CANCER RES (US) | 2022-03-10 | — | — | US | disclosed |
| EP-3920969-A1 | CONNEXIN 43 ANTIBODIES AND USE THEREOF | Alamab Therapeutics, Inc. (US) | 2021-12-15 | — | — | EP | disclosed |
| WO-2021134040-A2 | ENHANCING EXPRESSION OF LINE-1 ENCODED ORF2P FOR CANCER THERAPEUTICS | THE JOHNS HOPKINS UNIVERSITY (US) | 2021-07-01 | — | — | WO | disclosed |
| EP-3830123-A1 | ANTI-SIGLEC-5 ANTIBODIES AND METHODS OF USE THEREOF | Alector LLC (US) | 2021-06-09 | — | — | EP | disclosed |
| CN-112638944-A | anti-TIGIT antibody | 西进公司 | 2021-04-09 | — | — | CN | disclosed |
| US-20060172437-A1 | Method for manufacturing a carrier for chemical or biochemical assays | PEPSCAN SYSTEMS B.V. | 2006-08-03 | — | — | US | disclosed |
| EP-1641849-A1 | PHOTORESIST POLYMERS AND COMPOSITIONS HAVING ACRYLIC- OR METHACRYLIC-BASED POLYMERIC RESIN PREPARED BY A LIVING FREE RADICAL PROCESS | Symyx Technologies, Inc. (US) | 2006-04-05 | — | — | EP | disclosed |
| EP-1641848-A1 | PHOTORESIST POLYMER COMPOSITIONS | JSR Corporation (JP) | 2006-04-05 | — | — | EP | disclosed |
| WO-2005003198-A1 | PHOTORESIST POLYMER COMPOSITIONS | JSR CORPORATION (JP) | 2005-01-13 | — | — | WO | disclosed |
| WO-2005000923-A1 | PHOTORESIST POLYMERS AND COMPOSITIONS HAVING ACRYLIC- OR METHACRYLIC-BASED POLYMERIC RESIN PREPARED BY A LIVING FREE RADICAL PROCESS | SYMYX TECHNOLOGIES, INC. (US) | 2005-01-06 | — | — | WO | disclosed |
| EP-1377830-A2 | ARRAYS FOR DETERMINING BINDING OF BIOMOLECULES | PEPSCAN SYSTEMS B.V. (NL) | 2004-01-07 | — | — | EP | disclosed |
| WO-2002066984-A2 | ARRAYS FOR DETERMINING BINDING OF BIOMOLECULES | PEPSCAN SYSTEMS B.V. (NL) | 2002-08-29 | — | — | WO | disclosed |
| EP-1097381-A1 | METHOD FOR MANUFACTURING A CARRIER FOR CHEMICAL OR BIOCHEMICAL ASSAYS | PEPSCAN SYSTEMS B.V. (NL) | 2001-05-09 | — | — | EP | disclosed |
| WO-2000005584-A1 | METHOD FOR MANUFACTURING A CARRIER FOR CHEMICAL OR BIOCHEMICAL ASSAYS | PEPSCAN SYSTEMS B.V. (NL) | 2000-02-03 | — | — | WO | disclosed |
| WO-2000005583-A1 | PREPARATION CARRIER AND METHOD FOR ITS MANUFACTURE | STICHTING DIENST LANDBOUWKUNDIG ONDERZOEK (NL) | 2000-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220074941-A1 | HSP90 COMBINATION THERAPY | HSP90AB1, HSP90AB2P, HSP90B1 | ACHE 4880/4885EPHX1 3109/4885EPHX2 2619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.